1-3 of 3
Keith D. Wilner
Close
Sort by
Journal Articles

Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma

Clinical Trials & Observations
John P. Leonard, Ann S. LaCasce, Mitchell R. Smith, Ariela Noy, Lucian R. Chirieac, Scott J. Rodig, Jian Q. Yu, Shankar Vallabhajosula, Heiko Schoder, Patricia English, Donna S. Neuberg, Peter Martin, Michael M. Millenson, Scott A. Ely, Rachel Courtney, Naveed Shaik, Keith D. Wilner, Sophia Randolph, Annick D. Van den Abbeele, Selina Y. Chen-Kiang, Jeffrey T. Yap, Geoffrey I. Shapiro
Journal: Blood
Blood (2012) 119 (20): 4597–4607.
https://doi.org/10.1182/blood-2011-10-388298
Published: 2012
Includes: Supplemental data
Journal Articles

A Phase I Trial of PD 0332991, a Novel, Orally-Bioavailable CDK4/6-Specific Inhibitor Administered in Combination with Bortezomib and Dexamethasone to Patients with Relapsed and Refractory Multiple Myeloma.

Ruben Niesvizky, MD, Scott Ely, MD, MPH, David S Jayabalan, Megan C. Manco, Seema Singhal, MD, Mary Crann, Rachel Courtney, Cynthia DuFresne, Keith D. Wilner, PhD, Isan Chen, MD, Tomer Mark, MD, John P. Leonard, MD, Morton Coleman, MD, Maurizio DiLiberto, PhD, Xiangao Huang, PhD, Selina Chen-Kiang, PhD
Journal: Blood
Blood (2009) 114 (22): 1877.
https://doi.org/10.1182/blood.V114.22.1877.1877
Published: 2009
Journal Articles

Induction of sequential G1 arrest and synchronous S phase entry by reversible CDK4/CDK6 inhibition sensitizes myeloma cells for cytotoxic killing through loss of IRF-4.

Xiangao Huang, PhD, Maurizio Di Liberto, PhD, Scott Ely, MD, MPH, David S Jayabalan, BSMS, Isan Chen, MD, Keith D. Wilner, PhD, Malcolm Moore, DPhil, Ruben Niesvizky, MD, Selina Chen-Kiang, PhD
Journal: Blood
Blood (2009) 114 (22): 299.
https://doi.org/10.1182/blood.V114.22.299.299
Published: 2009